What is China Resources Medical Holdings Co EBITDA Margin %?
China Resources Medical Holdings CoFRA:1PH -0.75%54 EBITDA Margin % is 5.25% as of Dec. 2025, which is 65% below its 10-year median of 15.14. GuruFocus rates FRA:1PH with a GF Score™ of 54/100 and a GF Value™ of €0.43 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, China Resources Medical Holdings Co ranks worse than 55.24% on this metric.
China Resources Medical Holdings Co (FRA:1PH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Resources Medical Holdings Co EBITDA Margin % Related Terms
China Resources Medical Holdings Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Medical Holdings Co EBITDA Margin % Chart
FRA:1PH vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, China Resources Medical Holdings Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Medical Holdings Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, China Resources Medical Holdings Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where China Resources Medical Holdings Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Medical Holdings Co (FRA:1PH) has a EBITDA Margin % of 5.25% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Medical Holdings Co and its competitors. This is 65% below median its historical median of 15.14. According to the industry distribution chart, China Resources Medical Holdings Co ranks #369 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 55.2%.
Is China Resources Medical Holdings Co's EBITDA Margin % too high?
China Resources Medical Holdings Co's current EBITDA Margin % of 5.25% is 65% below median its 10-year median of 15.14. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. China Resources Medical Holdings Co's value of 5.25% is 48.6% below this industry median. Based on the distribution chart, China Resources Medical Holdings Co ranks #369 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, China Resources Medical Holdings Co has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Resources Medical Holdings Co's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, China Resources Medical Holdings Co ranks #369 out of 668 companies for EBITDA Margin %. This places China Resources Medical Holdings Co in the lower half of its industry. The industry median EBITDA Margin % is 10.21. China Resources Medical Holdings Co's value of 5.25% is 48.6% below this benchmark. While the company's 10-year median is 15.14 vs. the industry median of 10.21, China Resources Medical Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Medical Holdings Co's current EBITDA Margin % of 5.25% is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Medical Holdings Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Medical Holdings Co's current EBITDA Margin % is 5.25%, which is 65% below median its own 10-year median of 15.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Medical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Medical Holdings Co (FRA:1PH) is currently considered Possible Value Trap. The stock's GF Value™ is €0.43, compared to a current price of €0.26 — trading 38.6% below its estimated fair value. The current EBITDA Margin % is 5.25%, which is 65% below median its 10-year median of 15.14 and 48.6% below the Healthcare Providers & Services industry median of 10.21. China Resources Medical Holdings Co's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Resources Medical Holdings Co (FRA:1PH), the current EBITDA Margin % is 5.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Medical Holdings Co (FRA:1PH) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Medical Holdings Co stock appears to be undervalued.
The current stock price of €0.26 is trading 38.6% below its estimated GF Value™ of €0.43.
GuruFocus considers China Resources Medical Holdings Co to be Possible Value Trap.
Key valuation signals for FRA:1PH:
EBITDA Margin %: 5.25% (65% below median its 10-year median of 15.14)
GF Value™: €0.43 vs. price of €0.26 (38.6% below fair value)
Industry Position: 48.6% below the Healthcare Providers & Services median (#369 of 668)
No single metric tells the full story. See the FRA:1PH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Medical Holdings Co Business Description
China Resources Medical Holdings Co Ltd is engaged in the provision of general healthcare services; provision of hospital management services, sale of pharmaceuticals, medical devices, and medical consumables, and provision of other services in the Chinese Mainland. The group has two operating segments: Hospital Business and Other Business. The Hospital Business segment includes outpatient business and inpatient business corresponding to self-owned hospitals. The Other business segment includes operation management services, supply chain services, and other ancillary services provided to participating hospitals and IOT/OT hospitals. It generates the majority of its revenue from the Hospital Business segment.
54GF Score
Get the complete analysis for FRA:1PH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1PH has been successfully added to your 
